CAMBRIDGE, Mass.--(BUSINESS WIRE)--Galenea Corporation (“Galenea”) today announced that it has entered into a strategic neuroscience collaboration with Eisai Co. Ltd (“Eisai”). Under the collaboration, Galenea will apply its synaptic transmission platform technology to address synaptic dysfunction in neurodegenerative diseases. The collaboration’s goals are the discovery and development of novel therapeutics for neurodegeneration mediated by a disease-specific protein.